Cardiol Therapeutics Stock Forward View - Double Exponential Smoothing
| CRDL Stock | CAD 1.50 0.05 3.45% |
Cardiol Therapeutics's Double Exponential Smoothing reference data reflects the model's output when applied to available daily price observations. This page summarizes the model output and key accuracy metrics for reference. The projected value and error metrics are calculated from available daily price observations. This information is intended as reference material for analytical purposes.
The Double Exponential Smoothing forecasted value of Cardiol Therapeutics Class on the next trading day is expected to be 1.50 with a mean absolute deviation of 0.04 and the sum of the absolute errors of 2.41.When Cardiol Therapeutics Class prices exhibit either an increasing or decreasing trend over time, simple exponential smoothing forecasts tend to lag behind observations. Double exponential smoothing is designed to address this type of data series by taking into account any Cardiol Therapeutics Class trend in the prices. So in double exponential smoothing past observations are given exponentially smaller weights as the observations get older. In other words, recent Cardiol Therapeutics observations are given relatively more weight in forecasting than the older observations. The Double Exponential Smoothing reference values for Cardiol Therapeutics are derived from publicly available price data and should be used for informational purposes only. Double Exponential Smoothing Price Forecast For the 27th of March
Given 90 days horizon, the Double Exponential Smoothing forecasted value of Cardiol Therapeutics Class on the next trading day is expected to be 1.50 with a mean absolute deviation of 0.04 , mean absolute percentage error of 0.0026 , and the sum of the absolute errors of 2.41 .Please note that although there have been many attempts to predict Cardiol Stock prices using its time series forecasting, we generally do not suggest using it to place bets in the real market. The most commonly used models for forecasting predictions are the autoregressive models, which specify that Cardiol Therapeutics' next future price depends linearly on its previous prices and some stochastic term (i.e., imperfectly predictable multiplier).
Stock Forecast Pattern
| Backtest Cardiol Therapeutics | Cardiol Therapeutics Price Prediction | Research Analysis |
Forecasted Value
Forecasting Cardiol Therapeutics Class for the next session involves measuring the model's historical ability to define credible downside and upside scenarios. The projected forecast band currently runs from roughly 0.01 on the downside to about 5.07 on the upside.
Model Predictive Factors
The below table displays some essential indicators generated by the model showing the Double Exponential Smoothing forecasting method's relative quality and the estimations of the prediction error of Cardiol Therapeutics stock data series using in forecasting. Note that when a statistical model is used to represent Cardiol Therapeutics stock, the representation will rarely be exact; so some information will be lost using the model to explain the process. AIC estimates the relative amount of information lost by a given model: the less information a model loses, the higher its quality.| AIC | Akaike Information Criteria | Huge |
| Bias | Arithmetic mean of the errors | -0.0092 |
| MAD | Mean absolute deviation | 0.0402 |
| MAPE | Mean absolute percentage error | 0.0289 |
| SAE | Sum of the absolute errors | 2.415 |
Other Forecasting Options for Cardiol Therapeutics
Relative Strength Index values for Cardiol measure the speed and magnitude of recent price changes. Recognizing these clusters in Cardiol Therapeutics' returns helps calibrate position size and stop-loss levels. Candlestick pattern analysis of Cardiol Stock daily data can reveal short-term reversal or continuation signals. Identifying these patterns in Cardiol Stock data supports better trade timing.Cardiol Therapeutics Related Equities
The stocks listed below are peers of Cardiol Therapeutics within the Health Care space and offer context for ranking and strength. Profit comparisons show whether Cardiol Therapeutics earns above or below average returns next to its peers. Falling behind peers on key ratios may signal headwinds or execution issues worth looking into. Tracking Cardiol Therapeutics' results against these peers over time helps spot rising trends early.
| Risk & Return | Correlation |
Cardiol Therapeutics Market Strength Events
Market strength indicators provide a structured view of how Cardiol Therapeutics stock is positioned relative to trends. These indicators are valuable tools for identifying when to enter or exit positions in Cardiol Therapeutics Class. These signals help validate or refine position timing for Cardiol Therapeutics. Review these indicators alongside Cardiol Therapeutics's fundamental data for a complete analytical picture.
Cardiol Therapeutics Risk Indicators
The analysis of Cardiol Therapeutics' risk metrics is one of the most important steps in projecting its future price. This process quantifies the risk associated with Cardiol Therapeutics' and helps determine how to manage it. A structured analysis of Cardiol Therapeutics' risk indicators is one of the most reliable ways to improve forecast accuracy. Investors who carefully evaluate the risks in Cardiol Therapeutics' are better positioned to make informed decisions.
| Mean Deviation | 2.66 | |||
| Semi Deviation | 2.99 | |||
| Standard Deviation | 3.47 | |||
| Variance | 12.03 | |||
| Downside Variance | 11.32 | |||
| Semi Variance | 8.96 | |||
| Expected Short fall | -3.18 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Story Coverage note for Cardiol Therapeutics
The amount of media and story coverage tied to Cardiol Therapeutics Class can signal where market attention is concentrating at the moment. The stronger process compares story flow with performance, theme classification, and the level of short-term market interest.
Other Macroaxis Stories
Macroaxis story coverage is designed for a broad investing audience that ranges from self-directed traders to advisers, researchers, and institutional market participants. The content is intended to support people who want a more structured path from headline information to portfolio action.
Story Categories
Currently Trending Categories
Cardiol Therapeutics Short Properties
Short-interest signals around Cardiol Therapeutics Class can help investors judge whether skeptical positioning is starting to pressure price predictability and market tone. Used correctly, these measures can help investors decide when hedging or timing discipline may matter more than conviction alone.
| Common Stock Shares Outstanding | 71.6 M | |
| Cash And Short Term Investments | 30.6 M |
More Resources for Cardiol Stock Analysis
Understanding Cardiol Therapeutics starts with its core financial statements, trend data, and ratio analysis. The dataset reflects Cardiol Therapeutics' available reporting history.Use Historical Fundamental Analysis of Cardiol Therapeutics to cross-verify projections for Cardiol Therapeutics. Cardiol Therapeutics currently shows ROE of -3.48%, market cap of 161.94 Million. This analysis of Cardiol Therapeutics works best as a complementary layer when evaluating how the security fits in a broader portfolio. For Cardiol Therapeutics, the analytical tools below add portfolio-level context that single-security review alone cannot provide. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.